

National Essential Medicine List Medication Review Process
Adult Hospital Level
Component: Pain

Date: 15 October 2015

Medication: Ondansetron lyophilisate formulation.

Indication: Prevention of vomiting, in patients unable to tolerate oral preparations.

Final Question: How does the efficacy of an orally-disintegrating ondansetron tablet compare with a conventional oral ondansetron tablet in the prevention of chemotherapy-induced vomiting as an outpatient treatment in patients undergoing emetogenic chemotherapy?

P: patients undergoing emetogenic chemotherapy

I: orally-disintegrating ondansetron tablet

C: conventional oral ondansetron tablet

O: chemotherapy-induced vomiting

Evidence-based Answer: An orally-disintegrating ondansetron tablet provides similar efficacy as compared to a conventional oral ondansetron tablet in the prevention of chemotherapy-induced vomiting. Therefore, either formulation can be considered for an effective anti-emetic treatment on an outpatient basis for patients undergoing emetogenic chemotherapy. (Strength of Recommendation= B, based on two limited-quality controlled trials with patient-oriented evidence, an anti-emesis guideline and a guideline update).

Evidence Summary:

A randomized, multicenter, double-blind controlled trial was performed among 427 cancer patients receiving cyclophosphamide chemotherapy.¹ The study compared the anti-emetic efficacy and safety of orally-disintegrating tablet (ODT) with the conventional oral ondansetron tablet (OT). Patients were randomly assigned to receive 8 mg of an orally-disintegrating ondansetron tablet twice daily (ODT, n=215) or 8 mg of the conventional oral ondansetron tablet (OT, n=212) twice daily, for 3 days. In total, 78% (167/215) of patients in the ODT group achieved complete or major control of emesis on days one through three of chemotherapy, defined as less than two emetic episodes and no rescue medications, compared to 80% (169/212) of patients in the OT group (90% CI -8.6% to 4.4%). The 90% CI was within the predetermined -15% to 15% interval and therefore, no significant difference was found between the two groups and ODT was determined to be equivalent to OT in controlling emetic episodes. A limitation of this study may be the alternate cytotoxic agents patients were

receiving while enrolled in the trial, which may have altered the emetic risk category of the chemotherapy regimens.

A randomized, controlled, phase two trial was performed among 134 breast cancer patients receiving high-dose epirubicin.² The study compared the efficacy and safety of the novel orally-disintegrating tablet of ondansetron (ODT) and the conventional oral ondansetron tablet (OT) in chemotherapy-induced nausea and vomiting. Patients were randomly assigned to receive 8 mg ODT twice daily (n=66) or 8 mg OT twice daily (n=68), for 3 days. In total, 46 patients (70%) in the ODT group achieved complete or major control of emesis over the three day period, defined as zero to two emetic episodes and no rescue medications, compared to 52 patients (76%) in the OT group (p=0.28). A statistically significant difference was observed in the rate of complete emesis control (no emetic episodes and no rescue medications) for days one through three of chemotherapy, with 34 patients (52%) in the ODT group having no emetic episodes compared to 49 patients (72%) in the OT group (p=0.02). Limitations of this study may include lack of blinding, as well as subjective reporting of emetic episodes through the use of diary cards.

Recommendations from others:

The National Comprehensive Cancer Network (NCCN) published evidence driven guidelines for the management of emesis control in cancer patients.³ Recommendations made in these guidelines are based on the NCCN Categories of Evidence and Consensus (Categories 1, 2A, 2B, 3; based on level of evidence and overall NCCN consensus on appropriateness of the intervention). The guidelines recommend the use of ondansetron in anti-emetic therapy because it has shown to be effective in reducing nausea and vomiting resulting from chemotherapy. However, the use of orally-disintegrating ondansetron tablet compared to the conventional oral ondansetron tablet is not discussed in these guidelines.

In 2011, the American Society of Clinical Oncology (ASCO) published an update to the 2006 ASCO antiemetics guidelines in oncology.⁴ This update was evidence driven and based on a systematic review of the current oncology literature to evaluate newly added therapies. The guideline update states that the orally disintegrating ondansetron tablet is equivalent to the standard oral ondansetron tablet in controlling both emesis and nausea resulting from chemotherapy.

References:

1. Davidson N, Rapoport B, Erikstein B, et al. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. *Clin Ther.* 1999;21(3):492-502.
2. Pectasides D, Dafni U, Aravantinos G, et al. A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydys

in patients with breast cancer treated with high-dose epirubicin. *Anticancer Res.* 2007;27(6C):4411-4417.

3. Ettinger DS, Armstrong DK, Barbour S, et al. Antiemesis. *J Natl Compr Canc Netw.* 2012;10(4):456-485.
4. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol.* 2011;29(31):4189-4198.

Search Strategy:

Please note: The search strategy included additional clinical studies, but were not included as references in the Evidence Summary because they did not address the specific question for this clinical inquiry.

PubMed:

PubMed Clinical Queries

Results of searches on this page are limited to specific clinical research areas. For comprehensive searches, use [PubMed](#) directly.

Ondansetron AND vomiting AND chemotherapy AND formulations

Clinical Study Categories
Category:
Scope:

Systematic Reviews

Medical Genetics
Topic:

Results: 4 of 4
[Efficiency of using ondansetron in the surgical treatment of post-burn cicatricial deformity in children with a history of postoperative nausea and vomiting].
Lekmanov AJ, Tkachenko BA, Suvorov SG.
Anesteziol Reanimatol. 2009 Jan-Feb; 1(1):21-3.
[Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
Safonova SA, Gershanovich ML, Pusanov IuA, Kolygin BA.
Vopr Onkol. 1999; 45(4):424-8.
Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emetic Study Group.
Davidson N, Rapoport B, Erikstein B, L'Esperance B, Ruff P, Paaska W, Miller I, Curtis P.
Clin Ther. 1999 Mar; 21(3):492-502.
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Haigh CG, Kaplan LA, Durham JM, Dupeyron JP, Harmer M, Kenny GN.
Br J Anaesth. 1993 Oct; 71(4):517-22.
[See all \(4\)](#)

Results: 2 of 2
Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts.
McLean SL, Bienkinoop A, Bennett M.
J Pain Palliat Care Pharmacother. 2013 Jun; 27(2):132-6.
Epub 2013 Apr 29.
Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence.
Haigh CG, Kaplan LA, Durham JM, Dupeyron JP, Harmer M, Kenny GN.
Br J Anaesth. 1993 Oct; 71(4):517-22.
[See all \(2\)](#)

This column displays citations for systematic reviews, meta-analyses, reviews of clinical trials, evidence-based medicine, consensus development conferences, and guidelines. See [filter information](#) or [additional related sources](#).

Results: 0 of 0
This column displays citations pertaining to topics in medical genetics. See more [filter information](#).

Cochrane Library:



Search Search Manager Medical Terms (MeSH) Browse

Title, Abstract, Keywords

[Search Limits](#) [Search Help](#) (Word variations have been searched) [Add to Search Manager](#)

All Results (15)

- Cochrane Reviews (0)
- All
- Review
- Protocol
- Other Reviews (0)
- Trials (15)
- Methods Studies (0)
- Technology Assessments (0)
- Economic Evaluations (0)
- Cochrane Groups (0)

- All
- Current Issue

Cochrane Central Register of Controlled Trials : Issue 8 of 12, August 2015

There are 15 results from 887455 records for your search on 'ondansetron AND chemotherapy AND formulations in Title, Abstract, Keywords in Trials'

Sort by

Select all | Export all | Export selected

- A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer.
Corasoglou F and Sarper N
Pediatric hematology and oncology, 2005, 22(2), 103
Publication Year: 2005
- Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy.
Herrington JD, Kwan P, Young RR, Lagow E, Lagrone L and Riggs MW
Pharmacotherapy, 2000, 20(11), 1316
Publication Year: 2000

Guidelines:

Visit: National Quality Research Clearinghouse | AHRQ Home Sign In

Help | Videos | RSS | | Site map | Contact us | For web developers

[Search Tips](#) [Advanced Search](#) [About Search](#)

[Home](#) [Guidelines](#) [Expert Commentaries](#) [Guideline Syntheses](#) [Guideline Matrix](#) [Guideline Resources](#) [Compare Guidelines](#)

[Back](#)

'ondansetron' and 'emesis'
Run an advanced search on this term

Search within:

Sort results by: Relevance (what's this?) Publication date

Filter results by:

1-5 of 5

- Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients.** 2012. NGC:009337
Pediatric Oncology Group of Ontario - Professional Association. [View all guidelines by the developer\(s\)](#)
- Antiemetics: American Society of Clinical Oncology clinical practice guideline update, 1999 Sep (revised 2011 Nov 1).** NGC:009737
American Society of Clinical Oncology - Medical Specialty Society. [View all guidelines by the developer\(s\)](#)
- Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting.** 2007 Feb 1 (reaffirmed 2011). NGC:007737
Oncology Nursing Society - Professional Association. [View all guidelines by the developer\(s\)](#)
- Palliative care for the patient with incurable cancer or advanced disease. Part 2: pain and symptom management.** 2011 Sep 30. NGC:009466
Family Practice Oncology Network - Professional Association; Medical Services Commission, British Columbia - State/Local Government Agency (Non-U.S.). [View all guidelines by the developer\(s\)](#)

Clinical Trials:

ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Example: "Heart attack" AND "Los Angeles"
Search for studies:

[Advanced Search](#) | [Help](#) | [Studies by Topic](#) | [Glossary](#)

[Find Studies](#) | [About Clinical Studies](#) | [Submit Studies](#) | [Resources](#) | [About This Site](#)

Home > Find Studies > Search Results Text Size

13 studies found for: ondansetron AND formulations
[Modify this search](#) | [How to Use Search Results](#)

[List](#) | [By Topic](#) | [On a Map](#) | [Search Details](#)

+ Show Display Options

Include only open studies Exclude studies with Unknown status [Update List](#)

Rank	Status	Study
1	Completed Has Results	Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106) Condition: Chemotherapy-Induced Nausea and Vomiting Interventions: Drug: ondansetron clinical trial formulation; Drug: ondansetron marketed formulation
2	Completed	Open-label, Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation Condition: Healthy Interventions: Drug: Ond-PR1; Drug: Ond-PR1 + MPH-IR; Drug: Ond-PR2; Drug: Ond-PR2 +_ MPH-IR
3	Completed Has Results	A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED) Condition: Chemotherapy-Induced Nausea and Vomiting Interventions: Drug: Comparator: Treatment A (Zofran, ondansetron); Drug: Comparator: Treatment B (Zofran, ondansetron); Drug: Comparator: Treatment C (Zofran, ondansetron)

Abstracts:

1. Davidson N, Rapoport B, Erikstein B, et al. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. *Clin Ther.* 1999;21(3):492-502.

A total of 427 cancer patients receiving cyclophosphamide chemotherapy participated in this multicenter, double-masked, double-dummy, parallel-group, randomized study comparing the antiemetic efficacy and safety of an 8-mg conventional ondansetron tablet (OT, n = 212) taken twice daily with an 8-mg orally disintegrating ondansetron tablet (ODT, n = 215) taken twice daily for 3 days. In the primary efficacy analysis, complete or major control of emesis (0 to 2 emetic episodes) between days 1 and 3 was seen in 80% of OT and 78% of ODT patients. The 90% confidence interval for the differences between treatments was -8.6% to 4.4% (defined interval of equivalence, +/- 15%), showing that the formulations were equivalent. In the secondary efficacy analysis, no significant differences were observed in the rates of complete control of emesis (no episodes of emesis) over 3 days (63% and 64% of the respective groups) and on day 1 (84% and 81%, respectively) and in the complete control of nausea over 3 days (37% and 43%, respectively) and on day 1 (59% and 61% of patients, respectively). The taste of ODT was acceptable to the majority of patients (89%) who received it. OT and ODT were both well tolerated. Thus 8 mg ODT twice daily represents a palatable, well-tolerated, and effective antiemetic treatment for the control of cyclophosphamide-induced emesis and nausea and provides equivalent treatment to OT 8 mg twice daily.

2. Pectasides D, Dafni U, Aravantinos G, et al. A randomized trial to compare the efficacy

and safety of antiemetic treatment with ondansetron and ondansetron zydys in patients with breast cancer treated with high-dose epirubicin. *Anticancer Res.* 2007;27(6C):4411-4417.

Objective: The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast cancer patients. **Patients and Methods:** A total of 134 breast cancer patients receiving high dose epirubicin participated in a randomized trial comparing the antiemetic efficacy and safety of an 8 mg OT given twice daily to an 8 mg orally ODT given twice daily, both for 3 days. **Results:** OT was significantly better in the complete control of emesis (72% versus 52%, $p=0.020$) and marginally better in the complete control of nausea (66% versus 48%, $p=0.054$) induced by high-dose epirubicin over days 1-3 compared to ODT. However, no differences were found in major control of emesis (0 to 2 emetic episodes, 76% versus 70%, $p=0.28$) over days 1-3. **Conclusion:** OT was significantly better in the complete control of emesis and marginally better in the complete control of nausea, but not in the major control of emesis and nausea induced by high-dose epirubicin compared to ODT. ODT may be an effective alternative to OT, particularly in patients who have difficulties in swallowing a conventional tablet.

3. Ettinger DS, Armstrong DK, Barbour S, et al. Antiemesis. *J Natl Compr Canc Netw.* 2012;10(4):456-485.

No abstract available.

4. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol.* 2011;29(31):4189-4198.

Purpose: To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology. **Methods:** A systematic review of the medical literature was completed to inform this update. MEDLINE, the Cochrane Collaboration Library, and meeting materials from ASCO and the Multinational Association for Supportive Care in Cancer were all searched. Primary outcomes of interest were complete response and rates of any vomiting or nausea. **Results:** Thirty-seven trials met prespecified inclusion and exclusion criteria for this systematic review. Two systematic reviews from the Cochrane Collaboration were identified; one surveyed the pediatric literature. The other compared the relative efficacy of the 5-hydroxytryptamine-3 (5-HT₃) receptor antagonists. **Recommendations:** Combined anthracycline and cyclophosphamide regimens were reclassified as highly emetic. Patients who receive this combination or any highly emetic agents should receive a 5-HT₃ receptor antagonist, dexamethasone, and a neurokinin 1 (NK1) receptor antagonist. A large trial validated the equivalency of fosaprepitant, a single-day intravenous formulation, with aprepitant; either therapy is appropriate. Preferential use of palonosetron is recommended for moderate emetic risk regimens, combined with dexamethasone. For low-risk agents, patients can be offered

dexamethasone before the first dose of chemotherapy. Patients undergoing high emetic risk radiation therapy should receive a 5-HT₃ receptor antagonist before each fraction and for 24 hours after treatment and may receive a 5-day course of dexamethasone during fractions 1 to 5. The Update Committee noted the importance of continued symptom monitoring throughout therapy. Clinicians underestimate the incidence of nausea, which is not as well controlled as emesis.